Journal Article
. 2018 Oct; 379(20):1926-1936.
doi: 10.1056/NEJMoa1810527.

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C Turner 1 Dennis J Slamon 1 Jungsil Ro 1 Igor Bondarenko 1 Seock-Ah Im 1 Norikazu Masuda 1 Marco Colleoni 1 Angela DeMichele 1 Sherene Loi 1 Sunil Verma 1 Hiroji Iwata 1 Nadia Harbeck 1 Sibylle Loibl 1 Fabrice André 1 Kathy Puyana Theall 1 Xin Huang 1 Carla Giorgetti 1 Cynthia Huang Bartlett 1 Massimo Cristofanilli 1 
Affiliations
  • PMID: 30345905
  •     180 citations

Abstract

Background: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis of overall survival.

Methods: We randomly assigned patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus fulvestrant or placebo plus fulvestrant. We analyzed overall survival; the effect of palbociclib according to the prespecified stratification factors of presence or absence of sensitivity to endocrine therapy, presence or absence of visceral metastatic disease, and menopausal status; the efficacy of subsequent therapies after disease progression; and safety.

Results: Among 521 patients who underwent randomization, the median overall survival was 34.9 months (95% confidence interval [CI], 28.8 to 40.0) in the palbociclib-fulvestrant group and 28.0 months (95% CI, 23.6 to 34.6) in the placebo-fulvestrant group (hazard ratio for death, 0.81; 95% CI, 0.64 to 1.03; P=0.09; absolute difference, 6.9 months). CDK4/6 inhibitor treatment after the completion of the trial regimen occurred in 16% of the patients in the placebo-fulvestrant group. Among 410 patients with sensitivity to previous endocrine therapy, the median overall survival was 39.7 months (95% CI, 34.8 to 45.7) in the palbociclib-fulvestrant group and 29.7 months (95% CI, 23.8 to 37.9) in the placebo-fulvestrant group (hazard ratio, 0.72; 95% CI, 0.55 to 0.94; absolute difference, 10.0 months). The median duration of subsequent therapy was similar in the two groups, and the median time to the receipt of chemotherapy was 17.6 months in the palbociclib-fulvestrant group, as compared with 8.8 months in the placebo-fulvestrant group (hazard ratio, 0.58; 95% CI, 0.47 to 0.73; P<0.001). No new safety signals were observed with 44.8 months of follow-up.

Conclusions: Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant. The differences in overall survival in the entire trial group were not significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135 .).

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors.
Mariane Teodoro Fernandes, Jacob J Adashek, +5 authors, Pedro Nazareth Aguiar.
Drugs Context, 2018 Nov 13; 7. PMID: 30416529    Free PMC article.
Review.
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
A van Ommen-Nijhof, I R Konings, +5 authors, SONIA study steering committee.
BMC Cancer, 2018 Nov 22; 18(1). PMID: 30458732    Free PMC article.
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Rita S Mehta, William E Barlow, +9 authors, Gabriel N Hortobagyi.
N Engl J Med, 2019 Mar 28; 380(13). PMID: 30917258    Free PMC article.
Highly Cited.
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix.
Benjamin R Topacio, Evgeny Zatulovskiy, +6 authors, Jan M Skotheim.
Mol Cell, 2019 Apr 16; 74(4). PMID: 30982746    Free PMC article.
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
Gabriele Di Sante, Jessica Pagé, +4 authors, Richard G Pestell.
Expert Rev Anticancer Ther, 2019 Jun 21; 19(7). PMID: 31219365    Free PMC article.
Review.
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments.
Daniele Presti, Erica Quaquarini.
Cancers (Basel), 2019 Aug 28; 11(9). PMID: 31450618    Free PMC article.
Review.
ERα-targeted endocrine therapy, resistance and the role of GPER.
Richard A Pepermans, Eric R Prossnitz.
Steroids, 2019 Sep 14; 152. PMID: 31518595    Free PMC article.
Review.
Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo.
Ramesh Elango, Radhakrishnan Vishnubalaji, +6 authors, Nehad M Alajez.
Sci Rep, 2019 Sep 25; 9(1). PMID: 31548560    Free PMC article.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
George W Sledge, Masakazu Toi, +16 authors, Antonio Llombart-Cussac.
JAMA Oncol, 2019 Sep 30; 6(1). PMID: 31563959    Free PMC article.
Highly Cited.
Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer.
Long V Nguyen, Karlee Searle, Katarzyna J Jerzak.
Oncotarget, 2019 Nov 07; 10(59). PMID: 31695840    Free PMC article.
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.
Emanuel Raschi, Fabrizio De Ponti.
Front Pharmacol, 2019 Nov 12; 10. PMID: 31708776    Free PMC article.
Review.
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion.
Ahmad Awada, Joseph Gligorov, +3 authors, Christoph Zielinski.
ESMO Open, 2019 Dec 05; 4(6). PMID: 31798979    Free PMC article.
Review.
Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.
Hirohito Seki, Takashi Sakurai, +10 authors, Ken Shimizu.
In Vivo, 2019 Oct 31; 33(6). PMID: 31662535    Free PMC article.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Valentina Rossi, Paola Berchialla, +11 authors, Alessandra Fabi.
Cancers (Basel), 2019 Nov 14; 11(11). PMID: 31717791    Free PMC article.
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
Andreas D Hartkopf, Volkmar Müller, +16 authors, Diana Lüftner.
Geburtshilfe Frauenheilkd, 2019 Dec 27; 79(12). PMID: 31875860    Free PMC article.
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer.
Nina Ditsch, Marcus Schmidt.
Geburtshilfe Frauenheilkd, 2019 Dec 27; 79(12). PMID: 31875862    Free PMC article.
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Hitisha K Patel, Nianjun Tao, +6 authors, Teeru Bihani.
Breast Cancer Res, 2019 Dec 20; 21(1). PMID: 31852484    Free PMC article.
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy.
Irene De Santo, Amelia McCartney, +2 authors, Luca Malorni.
Cancers (Basel), 2019 Dec 05; 11(12). PMID: 31795152    Free PMC article.
Review.
Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
Chris Twelves, Sue Cheeseman, +9 authors, Tim Perren.
BMC Cancer, 2020 Jan 23; 20(1). PMID: 31964373    Free PMC article.
The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
Yaling Wang, Lin He, +4 authors, Xuezhen Ma.
BMC Womens Health, 2020 Feb 02; 20(1). PMID: 32005117    Free PMC article.
Evaluation of a charity-led secondary breast cancer support day: a model of survivorship care.
Barbara S Baker, Jean Marshall, Caroline J Hoffman.
Ecancermedicalscience, 2020 Feb 06; 13. PMID: 32010215    Free PMC article.
Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma.
Liang Chen, Qiuren Wei, Shuning Bi, Songqiang Xie.
Front Oncol, 2020 Feb 13; 10. PMID: 32047721    Free PMC article.
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
Daniele Frisone, Melinda Charrier, +8 authors, Petros Tsantoulis.
Cancer Biol Ther, 2019 Nov 12; 21(3). PMID: 31709901    Free PMC article.
In the literature: December 2019.
Valentina Gambardella, Amelia Insa, Juan-Miguel Cejalvo, Andrés Cervantes.
ESMO Open, 2020 Jan 21; 5(1). PMID: 31958287    Free PMC article.
Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
Jin Zhang, Qianying Wang, +3 authors, Zhengmao Zhu.
Cell Mol Life Sci, 2019 Sep 01; 77(4). PMID: 31471681
Review.
Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19-23 October 2018.
Martin Chopra.
Target Oncol, 2018 Nov 15; 13(6). PMID: 30426327
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Navid Sobhani, Alberto D'Angelo, +6 authors, Tobias Otto.
Cells, 2019 Apr 10; 8(4). PMID: 30959874    Free PMC article.
Review.
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review.
Junjie Li, Zhonghua Wang, Zhimin Shao.
Cancer Med, 2019 Apr 21; 8(5). PMID: 31004402    Free PMC article.
Review.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Lorenzo Rossi, Chiara Biagioni, +17 authors, Luca Malorni.
Breast Cancer Res, 2019 May 31; 21(1). PMID: 31142370    Free PMC article.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Barbara Adamo, Meritxell Bellet, +16 authors, Aleix Prat.
Breast Cancer Res, 2019 Sep 20; 21(1). PMID: 31533777    Free PMC article.
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.
Vassilis Aggelis, Stephen R D Johnston.
Drugs, 2019 Oct 21; 79(17). PMID: 31630379
Review.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Robert H Jones, Angela Casbard, +13 authors, Sacha J Howell.
Lancet Oncol, 2020 Feb 09; 21(3). PMID: 32035020    Free PMC article.
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
Erik S Knudsen, Steven C Pruitt, +2 authors, David W Goodrich.
Trends Cancer, 2019 Jun 09; 5(5). PMID: 31174843    Free PMC article.
Review.
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Johannes Ettl, Seock-Ah Im, +8 authors, Richard S Finn.
Breast Cancer Res, 2020 Mar 14; 22(1). PMID: 32164785    Free PMC article.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Kaitlyn J Andreano, Suzanne E Wardell, +15 authors, John D Norris.
Breast Cancer Res Treat, 2020 Mar 05; 180(3). PMID: 32130619    Free PMC article.
Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib.
Zoé Guillaume, Jacques Medioni, +3 authors, Audrey Simonaggio.
Clin Breast Cancer, 2020 Feb 24; 20(2). PMID: 32088132    Free PMC article.
eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer.
Tim Kong, Yibo Xue, +11 authors, Sidong Huang.
Mol Cancer Ther, 2019 Aug 10; 18(11). PMID: 31395685    Free PMC article.
Pan-cancer molecular analysis of the RB tumor suppressor pathway.
Erik S Knudsen, Ram Nambiar, +3 authors, Agnieszka K Witkiewicz.
Commun Biol, 2020 Apr 04; 3(1). PMID: 32242058    Free PMC article.
Drug repurposing for breast cancer therapy: Old weapon for new battle.
Sadhna Aggarwal, Sumit Singh Verma, Sumit Aggarwal, Subash Chandra Gupta.
Semin Cancer Biol, 2019 Sep 25; 68. PMID: 31550502    Free PMC article.
Review.
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
Monica Iorfida, Manuelita Mazza, Elisabetta Munzone.
Breast Cancer (Dove Med Press), 2020 Apr 08; 12. PMID: 32256106    Free PMC article.
Review.
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Lei Ding, Jiaqi Cao, +6 authors, Qinghua Cui.
Int J Mol Sci, 2020 Mar 19; 21(6). PMID: 32183020    Free PMC article.
Review.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Karen A Gelmon, Massimo Cristofanilli, +11 authors, Dennis J Slamon.
Breast J, 2019 Aug 27; 26(3). PMID: 31448513    Free PMC article.
The Role of CDK4/6 Inhibitors in Breast Cancer.
Conleth G Murphy.
Curr Treat Options Oncol, 2019 May 19; 20(6). PMID: 31101994
Review.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Review.
Standardized versus research-based PAM50 intrinsic subtyping of breast cancer.
A Prat, J S Parker.
Clin Transl Oncol, 2019 Aug 23; 22(6). PMID: 31435878
Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
Marco De Dominici, Patrizia Porazzi, +13 authors, Bruno Calabretta.
Blood, 2020 Feb 11; 135(18). PMID: 32040545    Free PMC article.
The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
Qi Du, Xiang Guo, +3 authors, Qin Li.
J Hematol Oncol, 2020 May 03; 13(1). PMID: 32357912    Free PMC article.
Review.
Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.
Georges El Hachem, Andrea Gombos, Ahmad Awada.
F1000Res, 2019 May 10; 8. PMID: 31069063    Free PMC article.
Review.
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Xi Jin, Li-Ping Ge, +4 authors, Yi-Zhou Jiang.
Mol Cancer, 2020 May 13; 19(1). PMID: 32393270    Free PMC article.
Low Overall Survival in Women With De Novo Metastatic Breast Cancer: Does This Reflect Tumor Biology or a Lack of Access to Health Care?
Leonardo R Soares, Ruffo Freitas-Junior, +3 authors, José C Oliveira.
JCO Glob Oncol, 2020 Apr 30; 6. PMID: 32348160    Free PMC article.
A population-based analysis of breast cancer incidence and survival by subtype in Ontario women.
S J Seung, A N Traore, +3 authors, K J Jerzak.
Curr Oncol, 2020 Jun 04; 27(2). PMID: 32489268    Free PMC article.
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
Yanmei Wu, Yu Zhang, Hao Pi, Yuan Sheng.
Cancer Manag Res, 2020 Jun 12; 12. PMID: 32523378    Free PMC article.
Review.
Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.
Ami N Shah, Otto Metzger, +3 authors, Massimo Cristofanilli.
Oncologist, 2020 Mar 17; 25(6). PMID: 32176406    Free PMC article.
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Jiani Zheng, Jingxun Wu, +3 authors, Feng Ye.
PLoS One, 2020 Jun 05; 15(6). PMID: 32497134    Free PMC article.
Systematic Review.
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Le-Sang Shen, Xiao-Yan Jin, +2 authors, Jian Huang.
Chin Med J (Engl), 2020 Apr 09; 133(9). PMID: 32265426    Free PMC article.
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers.
Erik S Knudsen, Geoffrey I Shapiro, Khandan Keyomarsi.
Am Soc Clin Oncol Educ Book, 2020 May 19; 40. PMID: 32421454    Free PMC article.
Review.
Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Ning Xie, Tao Qin, +3 authors, Huangming Hong.
Cancer Manag Res, 2020 Jun 26; 12. PMID: 32581595    Free PMC article.
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report.
Roberta Maltoni, Michela Palleschi, +5 authors, Andrea Rocca.
Medicine (Baltimore), 2020 Jun 17; 99(24). PMID: 32541460    Free PMC article.
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience.
Yi Li, Yizhao Xie, +7 authors, Biyun Wang.
Ther Clin Risk Manag, 2020 Jul 09; 16. PMID: 32636632    Free PMC article.
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
Laura M Spring, Seth A Wander, Mark Zangardi, Aditya Bardia.
Curr Oncol Rep, 2019 Feb 27; 21(3). PMID: 30806829    Free PMC article.
Review.
Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Huei Long, Chi-Tan Hu, Vesna Prijatelj, Ching-Feng Weng.
Medicine (Baltimore), 2020 Jul 08; 99(27). PMID: 32629666    Free PMC article.
Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors.
N J Lipton, J Jesin, +4 authors, K J Jerzak.
Curr Oncol, 2020 Jul 17; 27(3). PMID: 32669921    Free PMC article.
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.
Masato Takahashi, Norikazu Masuda, +7 authors, Masakazu Toi.
Cancer Med, 2020 May 19; 9(14). PMID: 32420697    Free PMC article.
Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.
Jocelyn Luveta, Ruth M Parks, +2 authors, Simon J Johnston.
Oncol Ther, 2020 Jul 24; 8(1). PMID: 32700069    Free PMC article.
Review.
Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer.
Mireia Margelí Vila, Sonia Del Barco Berron, +2 authors, Rafael Villanueva Vázquez.
Breast, 2020 Jul 06; 53. PMID: 32623094    Free PMC article.
Review.
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.
Marc Thill, Christian Jackisch, +42 authors, Nina Ditsch.
Breast Care (Basel), 2019 Sep 29; 14(4). PMID: 31558898    Free PMC article.
Review.
Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.
Qiao Huang, Si-Jia Zhai, +2 authors, Shi-Hua Yin.
J Oncol, 2020 Aug 01; 2020. PMID: 32733557    Free PMC article.
ABC4 Consensus: First Latin American Meeting-Assessment, Comments, and Application of Its Recommendations.
Henry L Gomez, Carlos Castañeda, +3 authors, Silvia Neciosup.
JCO Glob Oncol, 2020 Jun 17; 6. PMID: 32539467    Free PMC article.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Richard S Finn, Katalin Boer, +13 authors, Johannes Ettl.
Breast Cancer Res Treat, 2020 Jul 20; 183(2). PMID: 32683565    Free PMC article.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Lillian M Smyth, Kenji Tamura, +25 authors, David M Hyman.
Clin Cancer Res, 2020 Apr 22; 26(15). PMID: 32312891    Free PMC article.
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.
Masanori Oshi, Hideo Takahashi, +6 authors, Kazuaki Takabe.
Cells, 2020 Jul 12; 9(7). PMID: 32650578    Free PMC article.
Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.
Pauline du Rusquec, Cyriac Blonz, Jean Sebastien Frenel, Mario Campone.
Ther Adv Med Oncol, 2020 Aug 13; 12. PMID: 32782489    Free PMC article.
Review.
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Neil Portman, Heloisa H Milioli, +13 authors, Elgene Lim.
Breast Cancer Res, 2020 Aug 14; 22(1). PMID: 32787886    Free PMC article.
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group.
Elena Fountzilas, Georgia-Angeliki Koliou, +27 authors, Georgios Koumakis.
ESMO Open, 2020 Aug 21; 5(4). PMID: 32817060    Free PMC article.
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Elodie Montaudon, Joanna Nikitorowicz-Buniak, +35 authors, Elisabetta Marangoni.
Nat Commun, 2020 Aug 15; 11(1). PMID: 32792481    Free PMC article.
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
Mariana Brandão, Christian Maurer, +7 authors, Matteo Lambertini.
ESMO Open, 2020 Aug 28; 5(4). PMID: 32847835    Free PMC article.
Transcription Factors in Cancer Development and Therapy.
Kanchan Vishnoi, Navin Viswakarma, Ajay Rana, Basabi Rana.
Cancers (Basel), 2020 Aug 23; 12(8). PMID: 32824207    Free PMC article.
Review.
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Sudpreeda Chainitikun, James P Long, +4 authors, Naoto T Ueno.
Breast Cancer Res Treat, 2020 Jul 29; 183(3). PMID: 32720114    Free PMC article.
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
Lorenzo Rossi, Amelia McCartney, +3 authors, Angelo Di Leo.
Ther Adv Med Oncol, 2018 Dec 24; 10. PMID: 30574210    Free PMC article.
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.
Francesco Schettini, Irene De Santo, +8 authors, Lucia Del Mastro.
Front Oncol, 2019 Jan 12; 8. PMID: 30631751    Free PMC article.
Highly Cited. Review.
Palbociclib in metastatic breast cancer: current evidence and real-life data.
Francesco Serra, Pietro Lapidari, +3 authors, Raffaella Palumbo.
Drugs Context, 2019 Aug 09; 8. PMID: 31391852    Free PMC article.
Review.
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
Priyanka Bhateja, Mathew Cherian, Sarmila Majumder, Bhuvaneswari Ramaswamy.
Cancers (Basel), 2019 Aug 10; 11(8). PMID: 31394751    Free PMC article.
Review.
CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Amrallah A Mohammed, Hanaa Rashied, Fifi Mostafa Elsayed.
Oncol Rev, 2019 Aug 28; 13(2). PMID: 31452841    Free PMC article.
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra, Giuseppe Curigliano.
NPJ Breast Cancer, 2019 Sep 05; 5. PMID: 31482107    Free PMC article.
Review.
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.
Rossana Roncato, Jacopo Angelini, +6 authors, Giuseppe Toffoli.
Int J Mol Sci, 2020 Sep 05; 21(17). PMID: 32883002    Free PMC article.
Review.
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Michela Piezzo, Paolo Chiodini, +12 authors, Michelino De Laurentiis.
Int J Mol Sci, 2020 Sep 10; 21(17). PMID: 32899139    Free PMC article.
Systematic Review.
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Luc Cabel, Dan Rosenblum, +11 authors, François-Clément Bidard.
Breast Cancer Res, 2020 Sep 16; 22(1). PMID: 32928264    Free PMC article.
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Andreas Schneeweiss, Johannes Ettl, +31 authors, Sara Y Brucker.
Breast, 2020 Sep 22; 54. PMID: 32956934    Free PMC article.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, +42 authors, E P Winer.
Ann Oncol, 2020 Sep 27; 31(12). PMID: 32979513    Free PMC article.
Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis.
Chihwan Cha, Sung Gwe Ahn, +6 authors, Joon Jeong.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982652    Free PMC article.
Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.
Arnaud Beddok, Hao Ping Xu, +4 authors, Youlia Kirova.
Br J Cancer, 2020 Jul 01; 123(6). PMID: 32595213    Free PMC article.
Review.
Early treatment-related neutropenia predicts response to palbociclib.
Nicholas P McAndrew, Mark A Dickson, +10 authors, Angela DeMichele.
Br J Cancer, 2020 Jul 10; 123(6). PMID: 32641862    Free PMC article.
Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Maureen G Conlan, Erik F J de Vries, +2 authors, Steven Troy.
Eur J Drug Metab Pharmacokinet, 2020 Jul 15; 45(5). PMID: 32661909    Free PMC article.
Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers.
Jacob J Adashek, Ishwaria M Subbiah.
ESMO Open, 2020 Sep 24; 5(5). PMID: 32963088    Free PMC article.
Review.
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Yunzhen Qian, Yitao Gong, +8 authors, Chen Liu.
J Hematol Oncol, 2020 Oct 04; 13(1). PMID: 33008426    Free PMC article.
Review.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Richard S Finn, Massimo Cristofanilli, +11 authors, Hope S Rugo.
Breast Cancer Res Treat, 2020 Aug 13; 184(1). PMID: 32783178    Free PMC article.
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Michela Piezzo, Stefania Cocco, +8 authors, Michelino De Laurentiis.
Int J Mol Sci, 2020 Sep 10; 21(18). PMID: 32899866    Free PMC article.
Review.
Integrating Old and New Paradigms of G1/S Control.
Seth M Rubin, Julien Sage, Jan M Skotheim.
Mol Cell, 2020 Sep 19; 80(2). PMID: 32946743    Free PMC article.
Review.
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
Debora de Melo Gagliato, Antonio C Buzaid, +2 authors, Javier Cortes.
Cancers (Basel), 2020 Sep 05; 12(9). PMID: 32882980    Free PMC article.
Review.
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities.
Yifan Wang, Anna Lakoma, George Zogopoulos.
Genes (Basel), 2020 Sep 25; 11(9). PMID: 32967105    Free PMC article.
Review.
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia.
Jesús Fuentes-Antrás, Alicia de Luna, +3 authors, Fernando Moreno.
Breast, 2020 Oct 24; 54. PMID: 33096323    Free PMC article.
Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer.
Li Bian, Feng-Rui Xu, Ze-Fei Jiang.
Chin Med J (Engl), 2020 Aug 28; 133(19). PMID: 32852380    Free PMC article.
Eligibility of real-world patients with metastatic breast cancer for clinical trials.
Atul Batra, Shiying Kong, Winson Y Cheung.
Breast, 2020 Oct 30; 54. PMID: 33120082    Free PMC article.
Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis.
Siqi Liu, Xin Sun, Xiaohui Xu, Fangcai Lin.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154823    Free PMC article.
Review.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Hans Tesch, Volkmar Müller, +16 authors, Wolfgang Janni.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173239    Free PMC article.
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.
Mingxi Lin, Yang Chen, +2 authors, Jian Zhang.
J Cancer, 2020 Nov 17; 11(24). PMID: 33193875    Free PMC article.
Resistance and Overcoming Resistance in Breast Cancer.
Andrea Luque-Bolivar, Erika Pérez-Mora, Victoria Eugenia Villegas, Milena Rondón-Lagos.
Breast Cancer (Dove Med Press), 2020 Nov 19; 12. PMID: 33204149    Free PMC article.
Review.
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2-Rb wild-type and knock-down in breast cancer cell lines.
Oliviero Marinelli, Emanuela Romagnoli, +6 authors, Giorgio Santoni.
BMC Cancer, 2020 Nov 21; 20(1). PMID: 33213401    Free PMC article.
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Francesco Schettini, Fabiola Giudici, +17 authors, Daniele Generali.
J Natl Cancer Inst, 2020 May 15; 112(11). PMID: 32407488    Free PMC article.
Systematic Review.
Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε.
Vladislav O Sviderskiy, Lili Blumenberg, +14 authors, Richard Possemato.
Mol Cell, 2020 Nov 06; 80(4). PMID: 33152268    Free PMC article.
CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
Elisa Agostinetto, Rafael Caparica, Evandro de Azambuja.
ESMO Open, 2020 Nov 19; 5(6). PMID: 33203686    Free PMC article.
Major clinical research advances in gynecologic cancer in 2018.
Miseon Kim, Dong Hoon Suh, +4 authors, Jae Weon Kim.
J Gynecol Oncol, 2019 Feb 26; 30(2). PMID: 30806045    Free PMC article.
Review.
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
Wolfgang Janni, Andreas Schneeweiss, +14 authors, Johannes Ettl.
Geburtshilfe Frauenheilkd, 2019 Mar 19; 79(3). PMID: 30880825    Free PMC article.
Development and validation of a nomogram in survival prediction among advanced breast cancer patients.
Jianli Zhao, Yaping Yang, +15 authors, Ying Wang.
Ann Transl Med, 2020 Dec 15; 8(21). PMID: 33313191    Free PMC article.
CDK 4/6 inhibitors combined with radiotherapy: A review of literature.
Claire Bosacki, Wafa Bouleftour, +7 authors, Nicolas Magné.
Clin Transl Radiat Oncol, 2020 Dec 16; 26. PMID: 33319074    Free PMC article.
Review.
Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function.
Milad Rouhimoghadam, Anh S Lu, Aliasger K Salem, Edward J Filardo.
Front Endocrinol (Lausanne), 2020 Dec 18; 11. PMID: 33329395    Free PMC article.
Review.
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Andrea M Pesch, Nicole H Hirsh, +10 authors, Corey W Speers.
Clin Cancer Res, 2020 Sep 25; 26(24). PMID: 32967938    Free PMC article.
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.
Terry L Ng, Megan M Tu, +12 authors, Mark J Clemons.
Support Care Cancer, 2020 Jun 15; 29(2). PMID: 32535678
Systematic Review.
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
C Louwrens Braal, Elisabeth M Jongbloed, +3 authors, Agnes Jager.
Drugs, 2020 Dec 29; 81(3). PMID: 33369721    Free PMC article.
Review.
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
Serena Di Cosimo, Luca Porcu, Fatima Cardoso.
Breast, 2020 Dec 23; 55. PMID: 33352521    Free PMC article.
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Derek Dustin, Guowei Gu, +14 authors, Suzanne A W Fuqua.
Br J Cancer, 2020 Dec 02; 124(1). PMID: 33257837    Free PMC article.
Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
Amy E McCart Reed, Lauren Kalinowski, Peter T Simpson, Sunil R Lakhani.
Breast Cancer Res, 2021 Jan 09; 23(1). PMID: 33413533    Free PMC article.
Review.
The immunomodulatory effects of endocrine therapy in breast cancer.
Huanhuan Huang, Jun Zhou, +4 authors, Chao Ni.
J Exp Clin Cancer Res, 2021 Jan 09; 40(1). PMID: 33413549    Free PMC article.
Review.
Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature.
Steven David, Gwo Ho, +8 authors, Michelle White.
Transl Oncol, 2020 Nov 24; 14(1). PMID: 33227663    Free PMC article.
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Luis Manso, Cristina Hernando, +32 authors, Fernando Moreno.
Breast, 2020 Nov 27; 54. PMID: 33242755    Free PMC article.
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
B Porte, M Carton, +7 authors, P Cottu.
Breast, 2020 Nov 27; 54. PMID: 33242757    Free PMC article.
Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer.
Maithreyi Sarma, Yara Abdou, Ajay Dhakal, Shipra Gandhi.
Breast Cancer (Auckl), 2021 Jan 07; 14. PMID: 33402826    Free PMC article.
Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 Study.
Nina Odan, Yuichiro Kikawa, +8 authors, Shintaro Takao.
Breast Cancer (Auckl), 2021 Jan 16; 14. PMID: 33447040    Free PMC article.
Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer.
Andreas Schneeweiss, Ingo Bauerfeind, +5 authors, Volkmar Müller.
Breast Care (Basel), 2021 Jan 16; 15(6). PMID: 33447235    Free PMC article.
Review.
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Theresa E Hickey, Luke A Selth, +21 authors, Wayne D Tilley.
Nat Med, 2021 Jan 20; 27(2). PMID: 33462444
Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Shumei Kato, Ryosuke Okamura, +5 authors, Razelle Kurzrock.
JCI Insight, 2021 Jan 12; 6(1). PMID: 33427211    Free PMC article.
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Michela Roberto, Antonio Astone, +19 authors, Paolo Marchetti.
Cancers (Basel), 2021 Jan 23; 13(2). PMID: 33477469    Free PMC article.
Review.
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Gayathri Nagaraj, Cynthia X Ma.
Adv Ther, 2020 Nov 16; 38(1). PMID: 33190190    Free PMC article.
Review.
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.
Michelle M Williams, Nicole S Spoelstra, +15 authors, Jennifer K Richer.
Cancer Res, 2020 Nov 14; 81(3). PMID: 33184106    Free PMC article.
ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies.
Dimitra Stergiopoulou, Athina Markou, +4 authors, Evi Lianidou.
Cancers (Basel), 2021 Feb 05; 13(3). PMID: 33535614    Free PMC article.
Optimizing Palbociclib Therapy Across the Age Spectrum: Hypothetical, Illustrative Case Scenarios in HR+, HER2-Metastatic Breast Cancer.
Kimberly Podsada, Joanne C Ryan, Kristi Orbaugh.
J Adv Pract Oncol, 2021 Feb 13; 11(7). PMID: 33575067    Free PMC article.
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Silvana Mouron, Luis Manso, +6 authors, Maria J Bueno.
Breast Cancer Res, 2021 Feb 14; 23(1). PMID: 33579347    Free PMC article.
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Madeline M Cook, Luai Al Rabadi, +3 authors, Zahi I Mitri.
Oncologist, 2020 Nov 25; 26(2). PMID: 33230905    Free PMC article.
CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.
Wei Liu, Jin-Mou Yi, +8 authors, Hui Zeng.
Front Genet, 2021 Feb 19; 11. PMID: 33597968    Free PMC article.
An evaluation of palbociclib as a breast cancer treatment option: a current update.
Gregory T Gallanis, Ramon I Pericas, Anna T Riegel, Paula R Pohlmann.
Expert Opin Pharmacother, 2020 Nov 18; 22(3). PMID: 33198527    Free PMC article.
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Kamila Kaminska, Nina Akrap, +14 authors, Gabriella Honeth.
Breast Cancer Res, 2021 Feb 20; 23(1). PMID: 33602273    Free PMC article.
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies.
John F R Robertson, Angelo Di Leo, +6 authors, Christine Campbell.
NPJ Breast Cancer, 2021 Feb 14; 7(1). PMID: 33579962    Free PMC article.
Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2- Breast Cancer Patient With High Tumor Mutational Burden.
Rong Wang, Yuchen Yang, +6 authors, Wen-Ming Cao.
Front Oncol, 2021 Feb 27; 10. PMID: 33634015    Free PMC article.
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Jee Hyun Kim, Seock Ah Im, +4 authors, Sung Bae Kim.
J Breast Cancer, 2021 Feb 27; 24(1). PMID: 33634624    Free PMC article.
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents.
Giulia Petroni, Lorenzo Galluzzi.
Oncoimmunology, 2021 Mar 05; 10(1). PMID: 33659100    Free PMC article.
Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer.
Ryungsa Kim, Takanori Kin.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33672204    Free PMC article.
Review.
Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases.
C Fabregat-Franco, A Stradella, +13 authors, M J Gil-Gil.
Clin Transl Oncol, 2021 Mar 12;. PMID: 33704689
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Young-Hyuck Im, Bulent Karabulut, +13 authors, Sung-Bae Kim.
Breast Cancer Res Treat, 2021 Mar 18;. PMID: 33728524
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Norikazu Masuda, Hirofumi Mukai, +9 authors, Masakazu Toi.
Breast Cancer, 2020 Oct 22; 28(2). PMID: 33085032    Free PMC article.
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
Angela DeMichele, Massimo Cristofanilli, +8 authors, Richard S Finn.
Breast Cancer Res, 2021 Mar 26; 23(1). PMID: 33761995    Free PMC article.
Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study.
Raffaella Palumbo, Rosalba Torrisi, +11 authors, Erica Quaquarini.
Ther Adv Med Oncol, 2021 Apr 03; 13. PMID: 33796150    Free PMC article.
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Francesco Schettini, Mario Giuliano, +18 authors, Daniele Generali.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33810205    Free PMC article.
Review.
HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
Han Zhang, Jinlu Wang, +8 authors, Qingyuan Zhang.
Cancer Sci, 2021 Jan 17; 112(4). PMID: 33453094    Free PMC article.
Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review.
Asger S Paludan-Müller, Perrine Créquit, Isabelle Boutron.
BMC Med, 2021 Apr 09; 19(1). PMID: 33827569    Free PMC article.
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer.
Pin Zhang, Binghe Xu, +6 authors, Jianjun Zou.
Biomark Res, 2021 Apr 14; 9(1). PMID: 33845905    Free PMC article.
Arctigenin inhibits human breast cancer cell proliferation, migratory and invasive abilities and epithelial to mesenchymal transition by targeting 4EBP1.
Wenfang Luo, Fei Wang, Hewei Luo, Hui Liu.
Exp Ther Med, 2021 Apr 15; 21(6). PMID: 33850519    Free PMC article.
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.
Maria Alice Franzoi, Rita Saúde-Conde, +3 authors, Evandro de Azambuja.
Breast, 2021 Apr 03; 57. PMID: 33799232    Free PMC article.
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Debora Basile, Lorenzo Gerratana, +15 authors, Fabio Puglisi.
Breast, 2021 Apr 04; 57. PMID: 33812267    Free PMC article.
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Douglas I Lin, Jonathan K Killian, +3 authors, Julia A Elvin.
Mod Pathol, 2020 Oct 21; 34(5). PMID: 33077920
Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors.
Lucrezia Raimondi, Filippo Maria Raimondi, +6 authors, Gian Paolo Spinelli.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33923563    Free PMC article.
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
Malinda T West, Claire E Smith, +7 authors, Joseph J Shatzel.
Eur J Haematol, 2021 Feb 03; 106(5). PMID: 33527479    Free PMC article.
Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Jinming Li, Xingfa Huo, +5 authors, Jiuda Zhao.
JAMA Netw Open, 2020 Oct 14; 3(10). PMID: 33048129    Free PMC article.
Systematic Review.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Lillian M Smyth, Gerald Batist, +24 authors, Sarat Chandarlapaty.
NPJ Breast Cancer, 2021 Apr 18; 7(1). PMID: 33863913    Free PMC article.
Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer: a Brazilian private payer perspective.
Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne, Stephen Stefani.
Ther Adv Med Oncol, 2021 May 06; 13. PMID: 33948121    Free PMC article.
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.
Martina Silvestri, Antonio Cristaudo, +5 authors, Norma Cameli.
Drug Saf, 2021 May 08;. PMID: 33959899
Review.
Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features.
Alok Kumar Dwivedi, Rakesh Shukla.
Cancer Rep (Hoboken), 2020 Aug 15; 3(4). PMID: 32794640    Free PMC article.
Review.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Richard S Finn, Hope S Rugo, +11 authors, Véronique Diéras.
Oncologist, 2021 Jan 25; 26(5). PMID: 33486783    Free PMC article.
Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.
Thomas Benjamin Karasic, Mark H O'Hara, +6 authors, Peter J O'Dwyer.
Oncologist, 2020 Jul 22; 25(12). PMID: 32692450    Free PMC article.
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Muriel Lainé, Sean W Fanning, +6 authors, Geoffrey L Greene.
Breast Cancer Res, 2021 May 14; 23(1). PMID: 33980285    Free PMC article.
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
T Grinda, A Antoine, +24 authors, S Delaloge.
ESMO Open, 2021 Apr 26; 6(3). PMID: 33895695    Free PMC article.
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
Jason Schick, Raquel P Ritchie, Carolina Restini.
Breast Cancer (Auckl), 2021 May 18; 15. PMID: 33994789    Free PMC article.
Review.
Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis.
Hongna Lai, Wei Jiang, +5 authors, Herui Yao.
J Cancer, 2021 May 18; 12(12). PMID: 33995631    Free PMC article.
First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.
Anna Hester, Franziska Henze, +2 authors, Rachel Wuerstlein.
Breast Care (Basel), 2021 May 21; 16(2). PMID: 34012367    Free PMC article.
Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?
Athanasios Mavratzas, Frederik Marmé.
Breast Care (Basel), 2021 May 21; 16(2). PMID: 34012366    Free PMC article.
Review.
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women.
Eunae Jeong, Changjun Wang, Leslie Wilson, Lixian Zhong.
Front Oncol, 2021 May 25; 11. PMID: 34026637    Free PMC article.
The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
Brad A Davidson, Sarah Croessmann, Ben H Park.
Br J Cancer, 2021 May 28;. PMID: 34040179
Review.
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
Mario Hlevnjak, Markus Schulze, +28 authors, Andreas Schneeweiss.
JCO Precis Oncol, 2021 May 27; 5. PMID: 34036222    Free PMC article.
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Samitha Andrahennadi, Amer Sami, +2 authors, Shahid Ahmed.
Curr Oncol, 2021 Jun 03; 28(3). PMID: 34064867    Free PMC article.
Review.
A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Masanori Oshi, Fernando A Angarita, +4 authors, Kazuaki Takabe.
Cancers (Basel), 2021 Jun 03; 13(10). PMID: 34065619    Free PMC article.
Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer.
Miriam González-Conde, Celso Yañez-Gómez, Rafael López-López, Clotilde Costa.
J Pers Med, 2021 Jun 03; 11(5). PMID: 34068388    Free PMC article.
Review.